Abstract
INTRODUCTION
Indication of sublobar resection for small-sized lung carcinomas has been discussed openly, but remains an unresolved issue in recent general thoracic surgery. In 1995, the only randomized prospective trial comparing lobectomy with sublobar resections conducted by a Lung Cancer Study Group (LCSG) found a significantly higher recurrence rate for sublobar resections, and lobectomy has been favoured for resection of clinical-stage IA nonsmall-cell lung carcinoma (NSCLC) [1] . However, recent refinement of thin-section computed tomography (CT) has made it possible to detect early-stage lung cancers [2] . Moreover, it is well known that a ground-glass opacity (GGO) component is a strong favourable prognostic indicator of lung adenocarcinoma. A GGO appearance correlates well with histologic lepidic growth, and in most cases, their pathologic features are minimally invasive [3] [4] [5] [6] . Therefore, these populations are considered to be feasible candidates for sublobar resections, i.e. segmentectomy or wedge resection [7, 8] .
In contrast, consensus is yet to be reached concerning the indication of segmentectomy for lung carcinomas with a solid appearance on thin-section CT scan [9] [10] [11] [12] [13] . Several institutional retrospective studies have suggested that survival and recurrence may be almost equivalent between lobectomy and sublobar resection in patients with small-sized lung cancers 2 cm or less in size [14] [15] [16] . Based on results of the above studies, the efficacy of sublobar resection has now been investigated prospectively for clinical-T1a radiologically part-solid or pure-solid lung cancers in both Japan [17] and the USA [18] . Traditionally, however, postoperative nodal involvement is often found among patients with clinical-stage IA NSCLC, provided that a tumour shows radiologically solid appearance [12, 19, 20] . Therefore, a radiologically determined solid lung cancer was considered to be more malignant than GGO dominant tumours. Appropriate surgical modes for invasive lesions has been studied, however, the prognostic significance of segmentectomy in patients with radiological solid lung carcinomas is currently not well known [8] [9] [10] [11] [12] [13] [14] [15] [16] . Hence, the objective of this study was to evaluate the validity of pulmonary segmentectomy based on the oncological outcomes for clinicalT1aN0M0 radiologically solid, i.e. invasive NSCLC.
MATERIALS AND METHODS

Patients
Between January 2008 and April 2014, among 1269 patients who had undergone segmentectomy or lobectomy for lung cancer, 353 (28%) with clinical-T1aN0M0 radiologically invasive NSCLC on thin-section CT who had undergone standard lobectomy or segmentectomy with node dissections for radical resection were enrolled as subjects. Patients who had undergone wedge resection were excluded in order to evaluate postoperative locoregional recurrence after anatomical pulmonary resection with lymph node dissection. Any preoperative chemo-or radiotherapy was excluded from this study.
Radiological evaluations on thin-section CT scan
For all patients, preoperative thin-section CT scan findings were reviewed by the authors (A.H., T.M. and K.S.). Tumour size was determined preoperatively based on the thin-section CT scan findings. In addition, all tumours were subsequently evaluated to estimate the extent of GGO by thin-section CT scan with a 2 mm collimation. The solid component was defined as an area of increased opacification that completely obscured the underlying vascular markings [19, 20] . GGO was defined as an area of slight, homogeneous increase in density that did not obscure the underlying vascular markings [19, 20] . In the current study, the ratio of the maximum diameter of consolidation to the maximum tumour diameter was defined as consolidation tumour ratio (CTR) [6] , and a radiologically invasive tumour was defined as a lung tumour with 0.5 < _ CTR < _ 1.0 [6] . Of such tumours, a part-solid tumour was defined as a lung tumour with a GGO component, i.e. 0.5 < _ CTR < 1.0, while a pure-solid tumour was defined as a tumour showing only consolidation without GGO on thin-section CT, i.e. CTR = 1.0 (Fig. 1) . Any clinical-T1aN0M0 GGO dominant lung cancer with 0 < _ CTR < 0.5 was excluded from this study. Positron emission tomography (PET) was assessed for all patients. With regards to the clinical nodal assessment, the findings on preoperative thin-section CT scan and PET were reviewed for all, and clinical-N0 meant non-enlarged lymph nodes on CT scan or no uptake on PET.
Operation policy
A major lung dissection with systematic or selective lymph node dissection is indicated for clinical-T1aN0M0 radiologically invasive lung cancer at our institution [12, 20] , whereas intentional segmentectomy with systematic or selective lymph node dissection is now indicated for part-solid or pure-solid lung cancers 2 cm or smaller in size according to a prospective randomized trial in Japan [17] . Even when segmentectomy is performed, the procedure is promptly converted to lobectomy, if it becomes difficult to take sufficient surgical margins or lymph node metastasis is detected intraoperatively.
Follow-up policy
The postoperative follow-up was decided by each surgeon in our institute based on the pathological status of the tumours. The routine follow-up evaluation included a physical examination, chest radiography and blood tests including measurements of tumour makers every 6-12 months. A chest CT scan was performed periodically after surgical resection. If any symptom or sign of recurrence was found, further evaluation was performed including CT, brain magnetic resonance imaging, and PET. Locoregional recurrence was defined as occurrence within the same lobe, or in the ipsilateral thoracic cavity, and hilum or mediastinal lymph nodes, which was essentially diagnosed by the cytological or histological confirmation based on biopsy or surgical resection.
Statistics
Several clinicopathological factors were evaluated to assess the prognostic factors among the patients. The Mann-Whitney Utest or Chi-square test was used to compare two factors. Multivariate analysis was performed to identify the favourable prognostic factors by Cox proportional hazards model using SPSS Statistics 21 (SPSS Inc.). Forward and backward stepwise procedures were used to determine the combination of factors that were essential for predicting the prognosis. When Cox proportional hazards model was used to determine the significant prognostic factors for overall survival (OS) or loco-regional recurrence-free survival (LRFS), only potential preoperative confounding factors were assessed as variables because no postoperative factor could influence the decision on the surgical procedure. OS and LRFS were calculated by Kaplan-Meier estimation methods using log-rank test. The date of surgical resection was set as the starting point and the date of death or loco-regional recurrence due to all causes or last date of follow-up as the end point. Reported continuous data were shown with means and standard deviation (SD). Statistical analysis was considered significant when the P-value was less than 0.05.
RESULTS
The overall clinicopathological characteristics of the patients are summarized in Table 1 . Postoperative 30-day mortality was not observed in this cohort. The median follow-up period was 43 months. Table 2 summarizes the comparisons of the clinicopathological features between the two study arms. Among the 353 eligible patients, lobectomy was performed in 270 (76.5%) and segmentectomy in 83 (23.5%). Two patients converted the operative mode from segmentectomy to lobectomy. One patient changed due to the insufficient surgical margin, and the other was due to intraoperative positive lymph node by frozen diagnosis in this cohort. There were significant differences between the two groups with regards to several clinicopathological factors. Regarding both LRFS and OS, however, significant differences were not observed between the patients in the segmentectomy or lobectomy arms for clinical-T1a radiologically invasive NSCLC on the whole (3-year LRFS, 90.1 vs 93.0%, P = 0.2725, Fig. 2A ; 3-year OS: 96.3 vs 93.2%, P = 0.8014, Fig. 3A, respectively) .
Details of the loco-regional recurrence sites are, ipsilateral lymph node in 5 (83%), and intrapulmonary metastasis in 1 (17%) patient in the segmentectomy arm; and ipsilateral lymph node in 11 (61%), intrapulmonary metastasis in 3 (17%), malignant pleural effusion or pleural dissemination in 7 (39%) and bronchial stamp in 2 (11%) patients in the lobectomy arm. With regards to the treatment following detection of loco-regional recurrence, chemotherapy was administrated to 1 patient, and surgery was performed for intrapulmonary metastasis or lymph node recurrence in 2 patients in the segmentectomy arm, while chemotherapy was administrated to 8, and surgery was performed for intrapulmonary metastasis or lymph node recurrence in 2 patients in the lobectomy arm.
We evaluated clinical predictors of loco-regional recurrence in clinical-T1a radiologically invasive NSCLC. A multivariate Cox regression analysis revealed that a radiologically pure-solid appearance on thin-section CT scan [hazard ratio (HR), 5.051; 95% confidence interval (CI), 1.458-17.54; P = 0.0106] and maximum tumour size (mm) (HR, 1.170; 95% CI, 1.006-1.353; P = 0.0408) were significant predictors of loco-regional recurrence. Among the patients with loco-regional recurrence, 21 (87.5%) presented a pure-solid appearance on thin-section CT scan. Therefore, we evaluated the clinicopathological features of radiological partsolid and pure-solid lung cancer. As indicated, significant differences were found between the two study arms, and the characteristics of pure-solid lung cancer were significantly worse in many clinicopathological variables compared with those of partsolid one (Table 3) . With regards to the oncological outcomes, significant differences were observed between patients with radiological pure-solid and those with part-solid lung cancer regarding both LRFS and OS (3-year LRFS: 95.9 vs 83.0%, P = 0.0068; 5-year OS, 95.9 vs 84.0%, P = 0.0295). Thus, we analysed the significant clinical predictors of locoregional recurrence among the 212 patients with clinical-T1a radiologically pure-solid NSCLC. Table 4 summarizes the comparisons of the clinicopathological features between the two study arms. Among the 212 eligible patients, lobectomy was performed in 183 (86%) and segmentectomy in 29 (14%). There were significant differences between the two groups with regards to the clinicopathological characteristics including higher CEA, SUVmax, and lymphatic and vessel invasion in the lobectomy arm. In contrast, the frequency of loco-regional recurrence according to operative procedures was higher in the segmentectomy arm (6 patients, 20.7%) than that of lobectomy arm (15 patients, 8.2%). A multivariate analysis revealed that segmentectomy (HR, 2.924; 95% CI, 1.115-7.692; P = 0.0292) and larger tumour size (mm) (HR, 1.180; 95% CI, 1.007-1.383; P = 0.0402) were independently significant clinical factors of loco-regional recurrence.
Thus, we evaluated LRFS and OS according to consolidation status on thin-section CT scan. In 141 patients with clinical-T1a radiologically part-solid NSCLC, i.e. 0.5 < _ CTR < 1.0, both the 3-year LRFS and 3-year OS were excellent in both the segmentectomy and lobectomy arms (3-year LRFS, 98.0 vs 95.5%, P = 0.8628, Fig. 2B ; 3-year OS, 98.0 vs 97.5%, P = 0.6584, Fig. 3B , respectively). In contrast, the 3-year LRFS of the segmentectomy arm was significantly worse than that of the lobectomy arm when the tumour showed a radiologically pure-solid appearance on thin-section CT scan (3-year LRFS, 82.2 vs 90.6%, P = 0.0488, Fig. 2C ), although the 3-year OS was not significantly different despite the operative modes in this population (3-year OS, 93.1 vs 91.1%, P = 0.9491, Fig. 3C ).
DISCUSSION
There has been increasing evidences showing that in selected early stage patients, anatomical segmentectomy may be oncologically equivalent to lobectomy [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . In recent general thoracic surgery, however, one of the greatest concerns as for the indication of segmentectomy in patients with radiologically solid tumour is the potential risk for insufficiency of interlobar lymph node dissection and subsequent occult pathological nodal involvements, which is due to their highly invasive nature despite the small tumour size [21, 22] . Thus, it is still controversial whether segmentectomy may be equally effective in the management of part-solid or even pure-solid lesions, which are usually tumours with a more invasive behaviour. Therefore, we evaluated the incidence of loco-regional recurrence following segmentectomy against that following lobectomy in patients with clinical-T1a radiologically invasive NSCLC. From our results, loco-regional recurrence was frequently observed with a significant difference in the segmentectomy arm despite their small tumour size when the tumours showed a radiologically pure-solid appearance on thin-section CT scan. As indicated in previous literature, radiologically pure-solid lung carcinomas exhibit a more malignant behaviour and have a poorer prognosis compared with part-solid lung cancers [12, 19, 20, 23, 24] . In cases where oncologic results are equivalent, the potential benefits of segmentectomy include preserving vital lung tissue and providing the chance for further resection, if a second or third primary lung cancer develops. Thus, segmentectomy plays an important role as a treatment of patients with earlystage NSCLCs [13] . However, pure-solid lung cancers showed high frequencies of pathological nodal involvement even those in clinical-stage IA disease [12, 19, 20] . Thus, proper indication and prognostic significance of segmentectomy in such highly malignant tumours are controversial issues [14, 25, 26] .
In the present study, the subgroup analysis revealed that segmentectomy and lobectomy with hilar or mediastinal lymph node dissections had similar oncological outcomes in patients with clinical-T1a radiologically part-solid NSCLC with a GGO component (i.e. 0.5 < _ CTR < 1.0). The results suggested that selected subsets of patients showing radiologically part-solid lung cancers can be treated appropriately with segmentectomy without adversely affecting survival, despite their radiological invasive appearances. However, the 3-year LRFS of the segmentectomy arm was significantly worse than that of the lobectomy arm (82.2 vs 91.7%, P = 0.0488) when the tumour showed a pure-solid appearance on thin-section CT scan. Hence, segmentectomy should be cautiously applied for radiologically pure-solid lung carcinomas due to the expected high loco-regional recurrence rate compared to part-solid lung cancers.
With regards to OS in patients with clinical-T1a radiologically pure-solid lung cancer, a significant difference has not been observed between both operative modes so far. The reason might be associated with the relatively short follow-up period, the effect of adjuvant or post-recurrent chemotherapy or treatment after local recurrences including surgical salvage for intrapulmonary metastasis or lymph node recurrence. In contrast, the OS curve in this study showed a difference at 3 years after pulmonary resections between the 2 arms, and this feature of the survival curve was quite similar to that of LCSG in 1995 [1] . Hence, with regards to appropriate operative strategies, further follow-up is needed to investigate the contribution of these treatment arms to OS.
Concerning the operative policy for the resectable NSCLCs, a lobectomy with systematic lymph node dissection has been a standard surgical procedure [1] , whereas intentional segmentectomy with systemic or selective lymph node dissection is now indicated for clinical-T1aN0M0 radiologically invasive lung cancer in our institute based on the criteria of the JCOG 0802 prospective trials [17] . Regarding the indication of segmentectomy for small sized lung cancers, a tumour location that could obtain sufficient surgical margin is important for preventing cut-end surface recurrence by segmentectomy. Furthermore, intraoperative frozen section diagnosis for lymph nodes is warranted to confirm the negative lymph node status to prevent insufficient node dissection. However, local recurrence was frequently observed in the lymph nodes especially in patients underwent segmentectomy in this study, which may be related to the insufficiency of parenchymal resection or lymph nodal dissection.
In this study, patient selection for segmentectomy may have been very strict, as is shown in the comparison of clinicopathological characteristics of the patients in Table 2 . Nonetheless, the 3-year LRFS of the segmentectomy arm was significantly worse than the lobectomy arm, when the tumours showed radiological pure-solid appearance on thin-section CT. As for the efficacy of segmentectomy for clinical-T1a NSCLC with a radiologically partsolid or pure-solid appearance, the final results of the randomized phase III trials [17] should help us decide whether segmentectomy is appropriate for them. However, we would like to suggest that lobectomy with mediastinal lymph node dissection should be a standard surgical mode for tumours that show a radiological pure-solid appearance in order to perform strict loco-regional management, accurate nodal staging and proper administration of adjuvant therapy for these highly malignant tumours. When assessing the clinicopathological characteristics or prognostic impact of radiologically determined solid lung cancers, a thorough distinction between radiologically part-solid and pure-solid findings on thin-section CT scan is extremely important due to their distinct differences regarding the clinicopathological characteristics and oncological outcomes based on the presence of GGO components [27] . These findings should be taken into consideration when evaluating surgical outcomes of radiologically solid lung cancers.
This study was limited by a retrospective non-randomized nature, and relatively short median follow-up period. Furthermore, both lobectomy and segmentectomy arms should receive the same attention regarding the extent of LN dissection to compare the local recurrence. Therefore, the final results of the prospective phase III trials are awaited. Due to the highly invasive nature of radiologically pure-solid lung cancers, however, the result of this study could be informative when considering the validity of segmentectomy for pure-solid lung cancer. Further investigations are certainly warranted with regards to the appropriate operative strategies for these lesions.
In conclusion, even in cases of small-sized lung cancer, locoregional recurrence was frequently observed in radiologically pure-solid NSCLC patients who underwent pulmonary segmentectomy. Thus, segmentectomy should be applied with great caution in practice, especially for a radiological pure-solid NSCLCs on thin-section CT scan.
APPENDIX. CONFERENCE DISCUSSION
Dr W. Fang (Shanghai, China): This is a very meticulous study comparing local recurrence after segmentectomy and lobectomy in radiologically invasive clinical T1a lung cancer.
(Slide) We are all very familiar with this Lung Cancer Study Group trial comparing the results of lobectomy and segmentectomy, which found a 75% increase in recurrence and a tripling of local recurrence, which basically set up lobectomy as the gold standard for surgical treatment of early stage lung cancer.
However, there has been increasing evidence that segmentectomy may be oncologically equivalent, and potentially less risky, and preserves more pulmonary function and a safe window for future surgical treatment for a second pulmonary malignancy in selected patients. This is the well-known literature, again from the Japanese colleagues, which showed that for tumours less than 2 cm, lobectomy and segmentectomy, and even wedge resection, have similar outcomes, especially for GGO lesions. With the increased use of CT screening and more and more early stage lung cancer detected as small pulmonary nodules, it has been well recognized that segmentectomy, or even big wedge resections, could be enough for GGO lesions corresponding to low grade tumours which were classified as either AIS or MIA according to the 2011 IASLC histological classification. However, it is still controversial whether segmentectomy may be equally effective in the management of pure-solid lesions, which are usually tumours with more invasive behaviour.
In this study you found no difference in local recurrence between lobectomy and segmentectomy, and you did find that pure-solid appearance on CT scan as an independent risk factor for recurrence, which is even more significantly predictive than tumour size. You further studied patients with pure-solid lesions and found increased loco-regional recurrence after segmentectomy. Extent of resection was revealed, together with tumour size, as independent risk factors for local recurrence by multivariate analysis. So the 3-year recurrence-free survival after segmentectomy was significantly worse than lobectomy, which was 82 vs 91%. The discrepancy was only 10% compared to the Lung Cancer Study Group, which was 75%, although the overall survival was similar between groups.
So I think your conclusion is warranted, because the indication for segmentectomy should not be based only on the size of the tumour. Tumour biology should be carefully combined into decision-making and clinical practice. This is also in accordance with the current guidelines. For example, in the 2009 NCCN guidelines, limited resection was only reserved for physically compromised patients, but in the 2015 guidelines, segmentectomy is now considered an acceptable option for peripheral nodules less than 2 cm if they are a pure AIS histology, or nodules that have over 50% ground-glass opacity, or with a duplication time longer than 400 days.
I have two questions and you can answer them together. First, the overall recurrence rate was similar in the two study arms, and the 3-year overall survival for pure-solid lesions was similar between the two groups. So what actually was the indication for segmentectomy in your group, because you stated that intentional segmentectomy is now indicated in your patients for part-or puresolid lesions less than 2 cm, but it seems that the two groups are not so homogenous.
Secondly, I think you made the right conclusion that for pure-solid tumours, segmentectomy should be applied with great caution, even if they are smaller than 2 cm, but do you still think that segmentectomy may play a role in treating such patients? If so, what would be your indication? Is it based purely on the size of the tumour? If so, what do you think is the appropriate size for indicating segmentectomy, or would you include biomarkers and PET scan results into your decision-making? D. Hattori: These are really important questions. As for the first question with regard to the extent of resection, I showed in my slide that ipsilateral regional recurrence was the most frequent site in patients who underwent segmentectomy, and so at first everyone put their best effort into preventing loco-regional lymph node recurrence as much as possible. In that respect, tumour size and radiological appearance are really important factors in selecting segmentectomy because, as shown in the slides, these two factors are independently significant predictors of loco-regional recurrence-free survival. At the same time, these two clinical factors were also independently significant predictors of postoperative lymph node involvement in my previous study. So these two factors should be considered in the selection of segmentectomy.
Tumour location should also be considered, precisely because in order to prevent loco-regional recurrence, surgical margins should be secure. Bearing that in mind, tumour should be located in the periphery to prevent loco-regional recurrence. In addition, in order to prevent lymph node recurrence as much as possible, preoperative or intraoperative lymph node evaluation is needed. If it is suspected, EBUS or mediastinoscopy is indicated and intraoperative frozen diagnosis should be warranted to evaluate the lymph node status.
Dr E. Lim (London, UK): A number of Japanese studies have now advocated not doing any lymph node dissection if tumours are very small, peripheral, or have a GGO, and indeed some European guidelines recommend a limited lymph node dissection. Did the patients in your study who underwent segmentectomy have complete systematic nodal dissection as good as those who underwent lobectomy?
Dr Hattori: It depends on the patient's condition. All patients underwent at least regional sampling or dissection of hilar nodes, but maybe mediastinal regional dissection depends on the tumour condition in patients who are compromised, of course, and so on. In these patients we performed only hilar dissection.
Dr B. Stiles (New York, NY, USA): I think we obviously have to do more parenchymal-sparing procedures to compete with radiation therapy. So it is important we determine those patients in whom we can do that safely. I was also concerned or had a question about the nodes. I think for our literature it is very important that we define what is loco-regional recurrence, whether it is intraparenchymal versus N2 on the ipsilateral side. I was wondering if the study was able to determine that? For the segmentectomy patients who had ipsilateral nodal recurrences, were they in the parenchyma of the lung or was it N2 disease nodal recurrence?
Dr Hattori: Five patients showed ipsilateral regional recurrence and four patients were postoperative N0 and only one patient showed postoperative N2 disease.
Dr Stiles: So often the radiation oncologists won't count the N2 as locoregional recurrence. There is also literature on the margin with segmentectomy, and I was wondering if you looked at the margin as a factor of recurrence in these patients? The surgical margin in the segmentectomy patients, was that related to recurrence? 
